1. | Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348. |
2. | Matzke GR, Kovarik JM, et al. Evaluation of the vancomycin-clearance: creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm 1985;4:311-315. |
3. | Lake KS, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340-344. |
4. | Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985. |
5. | Rybak MJ, Boike SC. Monitoring vancomycin therapy. DICP 1986;20:757-761. |
6. | Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmaco 1986;11:257-282. |
7. | Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. DICP 1986;20:64-68. |
8. | Cheung RP, DiPiro JT. Vancomycin: An Update. Pharmacotherapy 1986;6:153-69. |
9. | Matzke GR. "Vancomycin" In: Applied Pharmacokinetics, Second Edition. Spokane, WA: Applied Therapeutics, Inc., 1986. pp 399-436. |
10. | Musa DM, Pauly DJ. Evaluation of a new vancomycin dosing method. Pharmacotherapy 1987;7:69-72. |
11. | Garrelts JC, Godley PJ, et al. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987;6:795-799. |
12. | Rodvold KA, et al. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-658. |
13. | Pyrka RD, Rodvold KA, et al. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Mon 1989 11:45-454. |
14. | Ackerman, Bruce H. Evaluation of three methods for determining initial vancomycin doses. DICP 1989;23:123-7. |
15. | Healy DP, et al. Vancomycin-induced histamine release and 'red man syndrome' comparison of 1- and 2-hour infusions. Antimicrobial Agents and Chemo 34; 550-554, 1990. |
16. | Pryka RD, Rovold KA, Erdman SM. An updated comparison of drug dosing methods part IV:vancomycin. Clin Pharmaco 1991;20:463-76. |
17. | Ito M, Duren L, et al. Computer program for the initiation of vancomycin therapy. Clin Farm 1993 12:126-30. |
18. | Leader WG, Chandler MH, and Castiglia M. Pharmacokinetic optimisation of Vancomycin therapy. Clin Pharmacokinet 28(4);327-42 1995. |
19. | Pou L, Rosell M, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Mon 1996 18:149-153. |
20. | Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981 Mar;94(3):343-6. |
21. | Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988; 32:848–52. |
22. | John E. Murphy; David E. Gillespie; Carol V. Bateman. Predictability of Vancomycin Trough Concentrations Using Seven Approaches for Estimating Pharmacokinetic Parameters. Am J Health-Syst Pharm. 2006;63(23):2365-2370. |
23. | Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Lodise TP, Lomaestro B, Graves J, Drusano GL. Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6. |
24. | Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82–98. |
25. | Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6. Epub 2008 Jan 28. |
26. | Vandecasteele SJ and De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney International 77, 760-764 (May 2010). |
See also:
Introduction
Monitoring parameters
Precautions
Pharmacokinetic formulas
|